Get in touch today 206.598.4100 or

Schedule an Appointment

Yolanda Tseng, M.D.

Assistant Professor


Dr. Tseng earned her MD and completed her radiation oncology residency program from Harvard Medical School. She believes that cancer is best treated with a team approach that includes other physicians, nurses, and technical staff involved in treatment planning. She has conducted research in diverse areas, including how physician estimate patient prognosis and its effects on treatment decisions, and how tumor biological subtypes affect patient outcomes and the response to local therapy. She is interested in systematically evaluating how proton radiotherapy can be used to optimize patient care. “As treatment efficacy improves for many disease sites, the goal now is to minimize the long-term side effects of our treatments. My hope is that we can achieve this for our patients.”

Patient Care Philosophy

One of the most anxious times during a cancer diagnosis is determining the plan of action. This requires a team approach, in which both patient and physician learn from each other about their priorities, goals, and expectations. It is important for my patients to feel well informed about their treatment options, since this allows us to make the best decision together about their care.

Education and Training

College:  Cornell University, Ithaca, NY, 2003

Graduate School: University of Cambridge, M.Phil., Cambridge, UK 2004

Medical Education: Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, MA 2009

Internship: Internal Medicine, Brigham and Women’s Hospital, Boston, MA 2010

Residency: Radiation Oncology, Harvard Radiation Oncology Program, Boston, MA 2014

Selected Publications from a Total of 26

Tseng YD, Krishnan MS, Sullivan AJ, Jones J, Chow E, Balboni TA. How radiation oncologists evaluate and incorporate life expectancy estimates into the treatment of palliative cancer patients: a survey-based study. Int J Radiat Biol Phys 2013; 87(3):471-8. PMID: 24074920. [published with editorial]

Krishnan M, Epstein-Peterson Z, Chen YH, Tseng YD, Wright AA, Temel JS, Catalano P, Balboni TA. Predicting life expectancy in patients with metastatic cancer receiving palliative radiotherapy: the TEACHH model. Cancer 2014; 120(1):134-41. PMID: 24122413.

Tseng YD, Krishnan M1, Jones JA, Sullivan AJ, Gorman D, Taylor A, Pacold M, Kalinowski B, Mamon HJ, Abrahm J, Balboni TA. The supportive and palliative radiation oncology service: impact of a dedicated service on palliative cancer care. Pract Radiat Oncol 2014; 4(4): 247-53. PMID: 25012833.

Tseng YD, Chen Y, Catalano P, Ng A. Rates and durability of response to salvage radiotherapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma. Int J Radiat Biol Phys 2015; 91(1): 223-31. PMID: 25835625.

Tseng YD, Apisarnthanarax S, Liao JJ, Bhatia S, Nghiem PT, Parvathaneni U. Factors influencing radiation treatment recommendations in early-stage Merkel cell carcinoma: A survey of US-based radiation oncologists. Expert Review of Anticancer Therapy 2017; 17(3): 281-287. PMID 28103445.

Hoppe B, Hill-Kayser CE, Tseng YD, Flampouri S, Elmongy H, Cahlon O, Mendenhall N, Maity A, McGee L, Plastaras JP. Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma. Ann Oncol 2017; 28(9): 2179-2184. PMID 28911093.

Tseng YD, Cutter DJ, Plastaras JP, Parikh R, Cahlon O, Chuong MD, Dedeckova K, Kahn, M, Lin SY, McGee L, Shen E, Terezakis S, Badiyan SN, Kirova YM, Hoppe RT, Mendenhall NP, Pankuch M, Flampouri S, Ricardi U, Hoppe B. Evidence-based review on the utilization of proton therapy in lymphoma from the Particle Therapy Cooperative Group lymphoma subcommittee. Int J Radiat Biol Phys 2017; 99(4): 825-842. PMID 28943076.

Tseng YD, Stevenson PA, Cassaday RD, Cowan A, Till BG, Shadman M, Graf SA, Ermoian R, Smith SD, Holmberg LA, Press OW, Gopal AK. Total body irradiation is safe and similarly effective to chemotherapy-only conditioning in autologous stem cell transplantation for mantle cell lymphoma patients. Biology of Blood and Marrow Transplantation 2018; 24: 282-287. PMID 29061536.

Tseng YD, Gouwens NW, Lo S, Halasz L, Mezheritsky IV, Loggers E. Use of Radiation Within the Last Year of Life Among Cancer Patients. Int J Radiat Biol Phys 2018; 101(1): 21-29. PMID 29487025.

Tseng YD, Nguyen MH, Baker K, Cook M, Redman M, Lachance K, Bhatia S, Liao JJ, Apisarnthanarax S, Nghiem PT, Parvathaneni U. Effect of host immune status on the efficacy of radiotherapy and recurrence-free survival among 805 Merkel cell carcinoma patients. Submitted and in review at Int J Radiat Biol Phys (in press).

To see more of Dr. Tseng’s publications, please click here.

Research Interests

  • Proton therapy for mediastinal lymphoma
  • Radiotherapy at the end of life
  • Impact of immune suppression on RT efficacy among patients with MCC
  • Impact of double/triple hit lymphoma pathology on RT efficacy among relapsed/refractory DLBCL patients